Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Public ClinicalTrials.gov record NCT02279862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic
Study identification
- NCT ID
- NCT02279862
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Interventions
- Ipilimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2014
- Primary completion
- Dec 14, 2016
- Completion
- Dec 14, 2016
- Last update posted
- Aug 27, 2019
2014 – 2016
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| San Francisco Oncology Associates | San Francisco | California | 94115 | — |
| George Washington University Medical Center | Washington D.C. | District of Columbia | 20037 | — |
| Baptist Cancer Institute | Jacksonville | Florida | 32207 | — |
| Cancer Center Of Kansas | Wichita | Kansas | 67214 | — |
| North Mississippi Med Center | Tupelo | Mississippi | 38801 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Northwest Cancer Specialists, Pc | Tualatin | Oregon | 97062 | — |
| University of Pittsburgh Cancer Institute Cancer Services | Pittsburgh | Pennsylvania | 15232-1305 | — |
| Texas Oncology | Houston | Texas | 77024 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02279862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02279862 live on ClinicalTrials.gov.